Analysts Set Conatus Pharmaceuticals Inc (CNAT) PT at $11.00

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has been given an average rating of “Buy” by the seven analysts that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $11.00.

A number of brokerages have recently issued reports on CNAT. Oppenheimer set a $14.00 target price on Conatus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 1st. ValuEngine raised Conatus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, September 22nd. Finally, HC Wainwright reissued a “buy” rating on shares of Conatus Pharmaceuticals in a research report on Monday, November 5th.

NASDAQ CNAT traded up $0.11 during trading hours on Friday, hitting $4.59. 4,812 shares of the company were exchanged, compared to its average volume of 564,178. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.39 and a quick ratio of 2.39. Conatus Pharmaceuticals has a 52-week low of $3.22 and a 52-week high of $7.95. The company has a market cap of $135.57 million, a price-to-earnings ratio of -7.64 and a beta of 1.99.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15). The business had revenue of $7.67 million for the quarter, compared to the consensus estimate of $9.70 million. Conatus Pharmaceuticals had a negative return on equity of 83.99% and a negative net margin of 52.77%. Equities research analysts anticipate that Conatus Pharmaceuticals will post -0.6 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC boosted its holdings in shares of Conatus Pharmaceuticals by 94.6% during the 3rd quarter. Virtu Financial LLC now owns 25,860 shares of the biotechnology company’s stock valued at $150,000 after buying an additional 12,572 shares in the last quarter. Artal Group S.A. bought a new position in Conatus Pharmaceuticals in the 3rd quarter worth about $2,900,000. BlackRock Inc. boosted its stake in Conatus Pharmaceuticals by 13.4% in the 3rd quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock worth $9,419,000 after purchasing an additional 191,287 shares in the last quarter. Jane Street Group LLC bought a new position in Conatus Pharmaceuticals in the 2nd quarter worth about $142,000. Finally, Paloma Partners Management Co bought a new position in Conatus Pharmaceuticals in the 2nd quarter worth about $547,000. 31.93% of the stock is owned by hedge funds and other institutional investors.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Read More: What Are Treasury Bonds?

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit